Recombinant Measles and Vesicular Stomatitis Virus are Ideal Adjunct to Checkpoint Immunotherapy

Recombinant Measles and Vesicular Stomatitis Virus are Ideal Adjunct to Checkpoint Immunotherapy

User Photo
AnnualMeeting-SITC2017

3 years
360 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Stephen J. Russell, MD, PhD of Mayo Clinic explains why recombinant measles and recombinant vesicular stomatitis virus are ideal adjunct to checkpoint immunotherapy. Both have shown impressive activity in pre-clinical models and clinical studies. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Up Next Autoplay